Literature DB >> 7697928

Enhanced production of transforming growth factor-beta (TGF-beta) during autologous mixed lymphocyte reaction of systemic sclerosis patients.

H Ota1, S Kumagai, A Morinobu, H Yanagida, K Nakao.   

Abstract

Systemic sclerosis (SSc) is characterized by systemic fibrosis and microvascular lesions. As TGF-beta is suggested to be related to skin fibrosis, we examined the production of TGF-beta from peripheral mononuclear cells (MNC) of SSc patients. Since anti-TGF-beta neutralizing antibody improved the defective proliferative response in autologous mixed lymphocyte reaction (AMLR) of SSc patients, TGF-beta was thought to participate in the decreased AMLR of SSc patients. Greater amounts of TGF-beta in the active as well as in the latent forms were produced during AMLR of SSc patients than that of normal subjects. It was suggested that TGF-beta excessively produced from the MNC of SSc patients might play a major role in the fibrosis of the patients during AMLR-like in vivo responses.

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 7697928      PMCID： PMC1534272          DOI： 10.1111/j.1365-2249.1995.tb03609.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN： 0009-9104            Impact factor:   4.330


  19 in total

1.  Cellular infiltrates in scleroderma skin.

Authors:  R Fleischmajer; J S Perlish; J R Reeves
Journal:  Arthritis Rheum       Date:  1977-05

2.  Transforming growth factor type beta: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro.

Authors:  A B Roberts; M B Sporn; R K Assoian; J M Smith; N S Roche; L M Wakefield; U I Heine; L A Liotta; V Falanga; J H Kehrl
Journal:  Proc Natl Acad Sci U S A       Date:  1986-06       Impact factor: 11.205

3.  Enhanced production of interleukin-2 in patients with progressive systemic sclerosis. Hyperactivity of CD4-positive T cells?

Authors:  H Umehara; S Kumagai; H Ishida; T Suginoshita; M Maeda; H Imura
Journal:  Arthritis Rheum       Date:  1988-03

4.  The transforming growth factor-beta system, a complex pattern of cross-reactive ligands and receptors.

Authors:  S Cheifetz; J A Weatherbee; M L Tsang; J K Anderson; J E Mole; R Lucas; J Massagué
Journal:  Cell       Date:  1987-02-13       Impact factor: 41.582

5.  Lymphocytes in the skin of patients with progressive systemic sclerosis. Quantification, subtyping, and clinical correlations.

Authors:  A D Roumm; T L Whiteside; T A Medsger; G P Rodnan
Journal:  Arthritis Rheum       Date:  1984-06

6.  Activation of HLA-DR and interleukin-6 gene transcription in resting T cells via the CD2 molecule: relevance to chronic immune-mediated inflammation.

Authors:  S Linardopoulos; V Corrigall; G S Panayi
Journal:  Scand J Immunol       Date:  1992-09       Impact factor: 3.487

7.  Collagen types synthesized in dermal fibroblast cultures from patients with early progressive systemic sclerosis.

Authors:  R E Gay; R B Buckingham; R K Prince; S Gay; G P Rodnan; E J Miller
Journal:  Arthritis Rheum       Date:  1980-02

8.  Early proliferative response in the human autologous mixed lymphocyte reaction in scleroderma.

Authors:  J Alcocer-Varela; A Laffón; D Alarcón-Segovia; G Ibañez de Kasep
Journal:  J Rheumatol       Date:  1984-02       Impact factor: 4.666

9.  Persistence of scleroderma-like phenotype in normal fibroblasts after prolonged exposure to soluble mediators from mononuclear cells.

Authors:  J G Worrall; T L Whiteside; R K Prince; R B Buckingham; I Stachura; G P Rodnan
Journal:  Arthritis Rheum       Date:  1986-01

10.  Production of transforming growth factor beta by human T lymphocytes and its potential role in the regulation of T cell growth.

Authors:  J H Kehrl; L M Wakefield; A B Roberts; S Jakowlew; M Alvarez-Mon; R Derynck; M B Sporn; A S Fauci
Journal:  J Exp Med       Date:  1986-05-01       Impact factor: 14.307
View more
  1 in total

1.  Cytokine and chemokine levels in systemic sclerosis: relationship with cutaneous and internal organ involvement.

Authors:  E Scala; S Pallotta; A Frezzolini; D Abeni; C Barbieri; F Sampogna; O De Pità; P Puddu; R Paganelli; G Russo
Journal:  Clin Exp Immunol       Date:  2004-12       Impact factor: 4.330
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.